Department of Histology and Embryology of School of Preclinical Medicine, Guilin Medical University, Guilin, Guangxi, People's Republic of China.
School of Stomatology, Zhaoqing Medical College, Zhaoqing, Guangdong, People's Republic of China.
J Cancer Res Clin Oncol. 2023 Nov;149(17):15763-15779. doi: 10.1007/s00432-023-05325-6. Epub 2023 Sep 5.
Lipoyltransferase 1 (LIPT1) has been recently identified as a cuproptosis‑related gene. As a key enzyme of lipoic acid metabolism, LIPT1 has been revealed to play important roles in hereditary diseases involved with lipoic acid biosynthesis defects, while its roles in hepatocellular carcinoma (HCC) remain to be elucidated. Hence, we aimed to explore the roles and mechanisms of LIPT1 in HCC progression.
The expression of LIPT1 in HCC tissues and its clinical significance for HCC were evaluated by bioinformatic analysis and in our patient cohort. The influences of LIPT1 on the growth, migration, and lipid metabolism of HCC cells were assessed in vitro. The underlying mechanisms were explored using gene set enrichment analysis (GSEA) and molecular experiments.
LIPT1 expression was significantly elevated in HCC tissues compared to the normal tissues, and such upregulation was associated with more malignant pathological features and poor prognosis of patients with HCC. LIPT1 silencing significantly inhibited cell proliferation, migration, and lipid content. GSEA revealed that LIPT1 upregulation was significantly associated with various cancer-associated signaling pathways, including the PI3K-AKT signaling pathway and the Wnt/β-catenin pathway. Further molecular experiments indicated that LIPT1 silencing repressed the expression of peroxisome proliferator-activated receptor gamma (PPARγ) and inactivated the AKT/GSK-3β/β-catenin signaling axis.
Upregulation of LIPT1 is involved in metabolic dysregulation of fatty acid and poor prognosis of HCC patients, which suggests that LIPT1 plays an important role in reprogramming lipid metabolism and could act as a potential prognostic marker and therapeutic target for HCC.
脂酰基辅酶 A 转移酶 1(LIPT1)最近被鉴定为与细胞铜死亡相关的基因。作为脂酸代谢的关键酶,LIPT1 已被揭示在涉及脂酸生物合成缺陷的遗传性疾病中发挥重要作用,而其在肝细胞癌(HCC)中的作用仍有待阐明。因此,我们旨在探讨 LIPT1 在 HCC 进展中的作用和机制。
通过生物信息学分析和我们的患者队列评估 LIPT1 在 HCC 组织中的表达及其对 HCC 的临床意义。在体外评估 LIPT1 对 HCC 细胞生长、迁移和脂质代谢的影响。使用基因集富集分析(GSEA)和分子实验探讨潜在机制。
与正常组织相比,LIPT1 在 HCC 组织中的表达显著升高,这种上调与更恶性的病理特征和 HCC 患者的不良预后相关。LIPT1 沉默显著抑制细胞增殖、迁移和脂质含量。GSEA 显示,LIPT1 上调与各种癌症相关的信号通路显著相关,包括 PI3K-AKT 信号通路和 Wnt/β-catenin 通路。进一步的分子实验表明,LIPT1 沉默抑制过氧化物酶体增殖物激活受体γ(PPARγ)的表达并使 AKT/GSK-3β/β-catenin 信号轴失活。
LIPT1 的上调参与了脂肪酸的代谢失调和 HCC 患者的不良预后,这表明 LIPT1 在重编程脂质代谢中发挥重要作用,并且可以作为 HCC 的潜在预后标志物和治疗靶点。